Compare Goldman Sachs Group Inc (GS) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance

Goldman Sachs (GS) trades at $893.95, down 0.15% with bearish technical signals but strong fundamental performance. The stock shows consistent earnings beats with Q3 2026 EPS of $17.01 exceeding expectations by 32%. Revenue growth accelerated to $58.28B in 2025 with net income margin improving to 29.46%. Recent news highlights the company's focus on expanding its $70B revenue base and AI initiatives.

GS presents a compelling value case with a P/E of 13.77 below industry averages, supported by 40% analyst buy ratings and a $1,130 consensus price target. However, negative operating cash flow trends and bearish technical indicators suggest near-term volatility. The dividend yield of approximately 0.56% provides income support while the company executes its growth strategy.

Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.

The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.